Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 404,478
  • Shares Outstanding, K 50,623
  • Annual Sales, $ 83,330 K
  • Annual Income, $ -227,100 K
  • EBIT $ -155 M
  • EBITDA $ -143 M
  • 60-Month Beta 1.05
  • Price/Sales 2.54
  • Price/Cash Flow N/A
  • Price/Book 2.61

Options Overview Details

View History
  • Implied Volatility 337.69% (+26.94%)
  • Historical Volatility 98.11%
  • IV Percentile 97%
  • IV Rank 65.29%
  • IV High 483.38% on 09/23/25
  • IV Low 63.68% on 09/05/25
  • Expected Move (DTE 4) 0.26 (3.19%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 710
  • Volume Avg (30-Day) 1,763
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 19,098
  • Open Int (30-Day) 11,709
  • Expected Range 7.74 to 8.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 6
  • High Estimate 0.16
  • Low Estimate -1.65
  • Prior Year -1.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.94 +0.63%
on 02/13/26
16.19 -50.65%
on 01/22/26
-7.06 (-46.91%)
since 01/13/26
3-Month
7.94 +0.63%
on 02/13/26
16.19 -50.65%
on 01/22/26
-3.65 (-31.36%)
since 11/13/25
52-Week
5.03 +58.69%
on 04/09/25
16.19 -50.65%
on 01/22/26
+0.67 (+9.15%)
since 02/13/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised...

RGNX : 7.99 (-4.31%)
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

ROCKVILLE, Md. , Feb. 9, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding...

RGNX : 7.99 (-4.31%)
Ongoing Investigation: REGENXBIO Inc. (RGNX) May Have Misled Shareholders - Levi & Korsinsky Investigates

New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...

RGNX : 7.99 (-4.31%)
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ:...

RGNX : 7.99 (-4.31%)
Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...

RGNX : 7.99 (-4.31%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised...

RGNX : 7.99 (-4.31%)
RGNX ALERT: Levi & Korsinsky Investigates REGENXBIO Inc. for Possible Securities Fraud Violations

New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...

RGNX : 7.99 (-4.31%)
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

ROCKVILLE, Md. , Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy,...

RGNX : 7.99 (-4.31%)
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

ROCKVILLE, Md. , Jan. 11, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal...

RGNX : 7.99 (-4.31%)
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44 th Annual J.P. Morgan Healthcare Conference.

RGNX : 7.99 (-4.31%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 9.12
2nd Resistance Point 8.88
1st Resistance Point 8.43
Last Price 7.99
1st Support Level 7.74
2nd Support Level 7.50
3rd Support Level 7.05

See More

52-Week High 16.19
Fibonacci 61.8% 11.93
Fibonacci 50% 10.61
Fibonacci 38.2% 9.30
Last Price 7.99
52-Week Low 5.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar